ESMO Breast 2025 | Expanding the role of PI3K/AKT pathway inhibitors in oncology

Andrea Botticelli • 21 May 2025

ESMO Breast 2025

Andrea Botticelli, MD, PhD, Sapienza University of Rome, Rome, Italy, comments on the potential of targeting the PI3K/AKT pathway in various types of cancer, beyond breast cancer, where PI3K/AKT inhibitors are already the standard of care. Other drugs, such as capivasertib and inavolisib, could be effective in targeting this pathway in different cancer types, highlighting the potential for a broader application of PI3K/AKT inhibitors in oncology. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

We know that today the PI3K/AKT inhibitors are the standard of care in our clinical practice. We know that we have several drugs such as capivasertib, rather than inavolisib, that could target this pathway. So maybe in an agnostic point of view, this pathway could be targeted for different types of cancer and not for breast cancer because breast cancer is today a standard of care...

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.